» Articles » PMID: 31905887

Protein Kinase B Inactivation Is Associated with Magnolol-Enhanced Therapeutic Efficacy of Sorafenib in Hepatocellular Carcinoma In Vitro and In Vivo

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2020 Jan 8
PMID 31905887
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Although sorafenib, an oral multikinase inhibitor, was approved as a treatment drug of advance hepatocellular carcinoma (HCC), treatment efficacy still requires improvement. Searching for the adjuvant reagent for enhancing sorafenib efficacy remains as a critical issue. Sorafenib has been proved to suppress extracellular signal-regulated kinases (ERK) in HCC; however, protein kinase B (AKT) was not affected by it. Targeting AKT in combination with sorafenib could be an important breakthrough point of HCC treatment. Many herbal compounds and composite formulas have been shown to enhance anti-HCC activity of sorafenib. Magnolol is a bioactive compound extracted from the bark of the and has been shown to induce apoptosis and inhibit cell invasion in HCC in vitro. However, whether magnolol sensitizes HCC to sorafenib is ambiguous. In this study, we indicated that magnolol significantly enhanced sorafenib-diminished tumor cell growth, expression of anti-apoptotic proteins, and migration/invasion ability compared to sorafenib alone. Magnolol significantly boosted sorafenib-induced extrinsic/intrinsic dependent apoptosis pathways in HCC. Notably sorafenib could not reduce protein level of AKT (Ser473), but expression of AKT (Ser473) was significantly decreased by magnolol or magnolol combined with sorafenib. LY294002 as specific AKT inhibitor was used to confirm that AKT inactivation may promote anticancer effect of sorafenib. Taken together, AKT inhibition is associated with magnolol-enhanced the therapeutic effect of sorafenib in HCC. We suggested magnolol as the potential adjuvant which may enhance therapeutic benefits of sorafenib in patients with HCC.

Citing Articles

Mechanistic insights of lenvatinib: enhancing cisplatin sensitivity, inducing apoptosis, and suppressing metastasis in bladder cancer cells through EGFR/ERK/P38/NF-κB signaling inactivation.

Chiang C, Yang J, Liu W, Chang F, Yang C, Hsu K Cancer Cell Int. 2025; 25(1):47.

PMID: 39955573 PMC: 11829490. DOI: 10.1186/s12935-024-03597-7.


fruit extracts enhance anti-cancer activity of sorafenib in HCT116 and HepG2 cells.

Parhira S, Simanurak O, Pansooksan K, Somran J, Wangteeraprasert A, Jiang Z Chin Herb Med. 2025; 17(1):108-126.

PMID: 39949813 PMC: 11814254. DOI: 10.1016/j.chmed.2024.11.007.


Chinese herbal medicine decreases incidence of hepatocellular carcinoma in diabetes mellitus patients with regular insulin management.

Lai H, Cheng J, Yip H, Jeng L, Huang S World J Gastrointest Oncol. 2024; 16(3):716-731.

PMID: 38577471 PMC: 10989382. DOI: 10.4251/wjgo.v16.i3.716.


Diallyl Disulfide Induces Chemosensitization to Sorafenib, Autophagy, and Cell Cycle Arrest and Inhibits Invasion in Hepatocellular Carcinoma.

Machado A, Tuttis K, Santos P, Aissa A, Antunes L Pharmaceutics. 2022; 14(12).

PMID: 36559076 PMC: 9788602. DOI: 10.3390/pharmaceutics14122582.


Frontier progress of the combination of modern medicine and traditional Chinese medicine in the treatment of hepatocellular carcinoma.

Wei L, Wang Z, Jing N, Lu Y, Yang J, Xiao H Chin Med. 2022; 17(1):90.

PMID: 35907976 PMC: 9338659. DOI: 10.1186/s13020-022-00645-0.


References
1.
Shimizu I . Sho-saiko-to: Japanese herbal medicine for protection against hepatic fibrosis and carcinoma. J Gastroenterol Hepatol. 2000; 15 Suppl:D84-90. DOI: 10.1046/j.1440-1746.2000.02138.x. View

2.
Tsuboi Y, Ichida T, Sugitani S, Genda T, Inayoshi J, Takamura M . Overexpression of extracellular signal-regulated protein kinase and its correlation with proliferation in human hepatocellular carcinoma. Liver Int. 2004; 24(5):432-6. DOI: 10.1111/j.1478-3231.2004.0940.x. View

3.
Plati J, Bucur O, Khosravi-Far R . Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities. J Cell Biochem. 2008; 104(4):1124-49. PMC: 2941905. DOI: 10.1002/jcb.21707. View

4.
Zhang H, Zhang Y, Cheng Y, Gong F, Cao Z, Yu L . Metformin incombination with curcumin inhibits the growth, metastasis, and angiogenesis of hepatocellular carcinoma in vitro and in vivo. Mol Carcinog. 2017; 57(1):44-56. DOI: 10.1002/mc.22718. View

5.
Macek Jilkova Z, Kuyucu A, Kurma K, Pour S, Roth G, Abbadessa G . Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma. Oncotarget. 2018; 9(13):11145-11158. PMC: 5834253. DOI: 10.18632/oncotarget.24298. View